We read with interest the article by Hamilos et al, 1 demonstrating a variable endothelium-dependent coronary vasomotor response at coronary segments adjacent to different drug-eluting stents (DES) and bare metal stents. In particular, a better coronary vasodilatation induced by pacing was observed in patients receiving zotarolimuseluting or biolimus A9 -eluting stents when compared with patients receiving paclitaxel-or sirolimus-eluting stents. As discussed by the authors, endothelial dysfunction after first-generation DES may be induced by the effect of the drug, its release kinetics, the proinflammatory effect of the polymer, or the combination of these factors. However, before drawing easy conclusions, several methodological considerations should be, in our opinion, clarified.
functional restoration are not defined. As described in pathologic studies, 5 sirolimus-and paclitaxel-eluting stents exhibit a delayed endothelialization when compared with conventional and newgeneration DES. Thus, one important finding of this study is the fact that different functional behavior may be related to different stages of endothelialization of different stents. Potentially, endothelial function of sirolimus-and paclitaxel-eluting stents may require longer follow-up to be restored than another DES with faster endothelialization. This hypothesis, however, remains to be demonstrated in serial functional analysis.
To minimize the amount of confounding variables involved in functional studies, a consensus on what, how, and when to measure is essential to demonstrate the differential pattern of endothelialization of a new generation of stent. 
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